Corcept execs enjoy raises in wake of drug OK


The San Francisco Business Times reports that Corcept Therapeutics execs earned 10% salary hikes after last year's approval of the Cushing's syndrome drug Korlym. CEO Joe Belanoff led the pack with an expanded $530,000 salary, up from $481,097. The rare-disease therapy costs up to $20,000 a month. Story